Floatz logo

Nst-628

Solid Tumor, Adult

Nested Therapeutics, IncPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

229 Active assets in the Solid Tumor, Adult cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Verastem, Inc.
Phase 2B
Nivolumab
ImmuneSensor Therapeutics Inc.
Phase 1/2B
FLUOROURACILUM
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 2B
Atezolizumab
KaliVir Immunotherapeutics
Phase 2B
Cyclophosphamide
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 2CCC

View all 50 →

Same molecule, other indications

Nst-628 is also rated in:

MEK MutationDormant
CC
Indicative ·
43 / 100
View asset →
neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Ras (KRAS or NRAS) Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →